Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Clinical trial NCT04150497 · RECRUITING
Trial details
- NCT number
- NCT04150497
- Sponsor
- Cellectis S.A.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-14
- Primary completion
- 2026-06-30
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.